Drug screening for α-synuclein aggregation inhibitors via multimodal graph neural network
Briefings in Bioinformatics · 01.03.2026 · 27 (2)
DOI: 10.1093/bib/bbag118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 23.03.2026. Verfasst von Tingle Gu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, Dalian Maritime University, No. 1 Linghai Road, Dalian 116026, Liao Ning, China. Hauptthemen laut MEDLINE: alpha-Synuclein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hainan Normal University, Ministry of Education.
Abstract (Originalsprache)
The pathological aggregation of α-synuclein (α-syn) constitutes a pivotal hallmark in the progression of neurodegenerative disorders, including Parkinson’s disease, underscoring the imperative need for identifying site-specific ligands. This study presents, for the first time, an advanced deep learning framework specifically designed for the prediction of molecular properties associated with α-syn. The framework integrates graph-based contextual attention mechanisms, structural feature aggregation protocols, and dual-channel feature integration, complemented by a composite regularization strategy that synergizes mean squared error minimization, Kullback–Leibler divergence–induced latent space regularization, and L2 norm penalization, thereby delivering outstanding predictive accuracy on the independent test dataset with MSE of 0.1812. Mechanistic insights derived from GNNExplainer analysis and molecular docking studies (PDB: 6A6B) elucidated that aromatic ring systems (benzene ring significance: 0.737) and hydrogen bond donor groups (amino group significance: 0.438) play critical roles in mediating high-affinity ligand–receptor interactions through π–π stacking within the hydrophobic pocket formed by Val82 and Ala89 residues, as well as directed hydrogen bonding involving catalytic residues Ser42 and Lys45. These findings not only enhance the understanding of inhibitor mechanisms but also establish a novel framework for the preliminary screening of small-molecule therapeutics, thereby laying a rigorous groundwork for structure-guided drug optimization and rational molecular design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Science, Dalian Maritime University, No. 1 Linghai Road, Dalian 116026, Liao Ning, China.
- College of Information Engineering, Northwest A&F University, No. 3 Taicheng Road, Yangling 712100, Shanxi, China.
- The First Clinical College, Liaoning University of Traditional Chinese Medicine, No. 79, Chongshen East Road, Huanggu District, Shenyang 110847, Liaoning, China.
- Department of Dermatology, Dalian Dermatosis Hospital, ChangJiang Road 788, Dalian 116021, Liaoning, China.
- South Australian immunoGENomics Cancer Institute (SAiGENCI), College of Health, Adelaide University, Adelaide 5005, Australia.
ORCID-Profile: Fuyi Li, Cangzhi Jia
Förderung
- National Natural Science Foundation of China
- Hainan Normal University, Ministry of Education
Zitieren
APA
Gu, T., Ran, Z., Li, W., Guo, X., Li, B., Li, F., & Jia, C. (2026). Drug screening for α-synuclein aggregation inhibitors via multimodal graph neural network. Briefings in Bioinformatics, 27(2). https://doi.org/10.1093/bib/bbag118
Vancouver
Gu T, Ran Z, Li W, Guo X, Li B, Li F, et al. Drug screening for α-synuclein aggregation inhibitors via multimodal graph neural network. Briefings in Bioinformatics. 2026;27(2). doi:10.1093/bib/bbag118
BibTeX
@article{Gu2026,
author = {Gu, Tingle and Ran, Zixu and Li, Wenyin and Guo, Xudong and Li, Bo and Li, Fuyi and Jia, Cangzhi},
title = {Drug screening for α-synuclein aggregation inhibitors via multimodal graph neural network},
journal = {Briefings in Bioinformatics},
year = {2026},
volume = {27},
number = {2},
doi = {10.1093/bib/bbag118}
}
EUVIMED